FIH

GreenFields Pure EP is the first certified Dry (non-irrigated) hockey turf

Retrieved on: 
Monday, June 19, 2023
Floris Jan Bovelander, International Hockey Federation, Greenfield, Hockey, Drinking, Water supply, International, Athlete, Philosophy, Sustainability, Water, EP, FIH, Olympic Games, Sports equipment

With Pure EP by GreenFields, a subsidiary of TenCate, global supplier of and innovator in artificial turf for sports fields, the field hockey world is taking a revolutionary step towards greater sustainability and the ongoing globalisation of field hockey.

Key Points: 
  • With Pure EP by GreenFields, a subsidiary of TenCate, global supplier of and innovator in artificial turf for sports fields, the field hockey world is taking a revolutionary step towards greater sustainability and the ongoing globalisation of field hockey.
  • Field hockey players say the new dry (non-irrigated) hockey turf rivals the quality of water-based artificial turf, while saving millions of litres of (drinking) water per year.
  • Field hockey club MHC Weesp is the proud owner of the world's first dry (non-irrigated) hockey turf field.
  • Furthermore, Pure EP will create a level playing field in the international world of field hockey.

Microbot Medical Announces Multiple Peer Reviewed Abstracts Accepted by The Cardiovascular and Interventional Radiological Society of Europe

Retrieved on: 
Friday, June 16, 2023
Abstract, KOL, Cardiovascular and Interventional Radiological Society of Europe, Validation, Investigation, Disposable product, ICR, ZEUS robotic surgical system, Internet, Clinical trial, Compact, CIRSE, Circulatory system, V&V, FIH, IDE, FDA, Conference, Investigational device exemption, Safety, Medical device, Robotics

Further displaying their positive experiences and satisfaction, the Company has been informed that two peer-reviewed abstracts have been accepted to be presented at the Annual Congress of the Cardiovascular and Interventional Radiological Society of Europe (CIRSE).

Key Points: 
  • Further displaying their positive experiences and satisfaction, the Company has been informed that two peer-reviewed abstracts have been accepted to be presented at the Annual Congress of the Cardiovascular and Interventional Radiological Society of Europe (CIRSE).
  • In addition, one of the abstracts was accepted as an oral presentation.
  • These peer-reviewed abstracts follow the highly successful extended joint pre-clinical animal studies held at leading European-based research labs by a team of seven renowned European interventional radiologists.
  • We believe that the current and future peer-reviewed data will accelerate adoption of LIBERTY once commercialized," said Dr. Eyal Morag, Chief Medical Officer of Microbot Medical.

Propanc Biopharma Announces Strategic Pharma Partnering Initiative

Retrieved on: 
Tuesday, June 6, 2023
Research, General Health, Pharmaceutical, Oncology, Hospitals, Genetics, Clinical Trials, Science, Surgery, Biotechnology, FDA, Health, OTC Markets Group, Metastasis, Skin, Cancer, Breast, Brain, Prostate, Trial of the century, Lung, Teaching hospital, Hospital, PRP, Patient, BAS, Chymotrypsinogen, Trypsinogen, Kidney, FIH, Growth, Liver, MEI, Recurrence, Death, Pharmaceutical industry, Medical imaging

Propanc Biopharma, Inc. (OTC Pink: PPCBD) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced the Company’s strategic pharma partnering initiative, as its lead product candidate, PRP, advances towards a Phase I, First-In-Human (FIH) study in advanced cancer patients.

Key Points: 
  • Propanc Biopharma, Inc. (OTC Pink: PPCBD) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced the Company’s strategic pharma partnering initiative, as its lead product candidate, PRP, advances towards a Phase I, First-In-Human (FIH) study in advanced cancer patients.
  • Over the past several years, management has initiated discussions with potential strategic collaborators to provide the resources to advance PRP into clinical development and for future commercialization.
  • The strategic goal of these potential collaborations is to develop and commercialize PRP for the treatment and prevention of metastatic cancer from solid tumors in major pharmaceutical markets worldwide.
  • Several other major companies were approached and Propanc expects to resume discussions during the next stage of clinical development for PRP.

Ractigen Therapeutics Announces Dosing of First Patient in First in Human Trial of RAG-17 for the Treatment of SOD1-ALS

Retrieved on: 
Monday, June 5, 2023
Central nervous system, Therapy, Clinical trial, Conjugation, Pharmacokinetics, Mutation, Biomarker, CNS, Small RNA, SOD1, Patient, SCAD, Sirna Therapeutics, FIH, CSF, ALS, Safety, Pharmaceutical industry

The FIH trial is designed to evaluate the safety, pharmacokinetics, pharmacodynamics (reduction of CSF biomarkers) and immunogenicity of RAG-17 in ALS patients with a confirmed SOD-1 mutation.

Key Points: 
  • The FIH trial is designed to evaluate the safety, pharmacokinetics, pharmacodynamics (reduction of CSF biomarkers) and immunogenicity of RAG-17 in ALS patients with a confirmed SOD-1 mutation.
  • "We are extremely pleased to initiate this first in human trial of RAG-17, marking our transformation into a clinical-stage company" said Dr. Long-Cheng Li, Ractigen’s Founder, President and Chief Executive Officer.
  • "This milestone highlights our commitment to building and strengthening our pipeline and clinical validation of our novel CNS delivery platform.
  • Given our mission to deliver innovative medicines to patients with high, unmet needs, we look forward to continued enrolment and dosing of patients in this trial" added Dr. Li.

Myrtelle to Present Positive 6-month Post-Treatment Data in Its First-in-Human Clinical Study of rAAV-Olig001-ASPA Gene Therapy in Canavan Disease at the National Tay-Sachs and Allied Diseases Annual Family Conference

Retrieved on: 
Wednesday, May 31, 2023
Neurology, Biotechnology, Pharmaceutical, General Health, Health, Genetics, Clinical Trials, Other Health, CD, Gross, Canavan disease, Inc., Drug development, Natural history, IV, Clinical trial, Mutation, Human, Brain, ASPA, AAV, Doctor of Philosophy, Language, NAA, System, MRI, MRS, Magnetic resonance imaging, Metabolism, MD, Patient, Preyasi Raave, White matter, CSF, FIH, Conference, Caregiver, Vaccine, Medical imaging, Myrtelle Canavan

Olga Flamini, MD, PhD, Medical Director at Myrtelle, will deliver a presentation on Friday, June 2, 2023.

Key Points: 
  • Olga Flamini, MD, PhD, Medical Director at Myrtelle, will deliver a presentation on Friday, June 2, 2023.
  • These improvements in treated patients contrast the deterioration in untreated age-matched CD patients in Myrtelle’s natural history data set.
  • In CD, normal brain development is impaired due to a mutation in the ASPA gene that encodes the enzyme aspartoacylase.
  • “Connecting with patients and caregivers allows us to incorporate the patient voice into our drug development activities.”

Valve Medical Announces Successful First-in-Human Implantation of Ultra-low Profile TAVR Valve in Israel

Retrieved on: 
Wednesday, May 31, 2023
Rabin Medical Center, Aortic stenosis, TEL, Percutaneous aortic valve replacement, Patient, Physician, Risk, Aortic valve, TAVR, Workload, FIH, Medical imaging, Dentistry

TEL AVIV, Israel, May 31, 2023 /PRNewswire/ -- Valve Medical, a wholly owned subsidiary of Medinol Ltd. is pleased to announce today the successful First-in-Human (FIH) implantation of their advanced Transcatheter Aortic Valve Replacement (TAVR) system in Israel, introducing a revolutionary advancement in Structural Heart procedures with the world's first modular valve.

Key Points: 
  • TEL AVIV, Israel, May 31, 2023 /PRNewswire/ -- Valve Medical, a wholly owned subsidiary of Medinol Ltd. is pleased to announce today the successful First-in-Human (FIH) implantation of their advanced Transcatheter Aortic Valve Replacement (TAVR) system in Israel, introducing a revolutionary advancement in Structural Heart procedures with the world's first modular valve.
  • The Valve Medical Xemed TAVR device is a transformational technology designed to improve patient outcomes and procedural success.
  • The distinguishing feature of the valve is its modular design, which has an ultra-low profile, enabling the use of a standard 12 Fr sheath.
  • TAVR is a minimally invasive procedure that replaces the damaged aortic valve with a new valve without the need for open-heart surgery.

Immorna Announces First Subject Dosed in a Phase 1 Study of JCXH-105, a Self-Replicating RNA-Based Vaccine Developed for the Prevention of Shingles

Retrieved on: 
Tuesday, May 30, 2023
Vaccine, Infection, GSK, Therapy, Biotechnology, RNA, Messenger, HZ, FIH, Ageing, ICMJE recommendations, Shingles, Safety

"The initiation of our FIH study with JCXH-105 is an important milestone for Immorna and for the development of a potential innovative vaccine for Shingles," said NgocDiep Le, M.D., Ph.D., Global Chief Medical Officer of Immorna.

Key Points: 
  • "The initiation of our FIH study with JCXH-105 is an important milestone for Immorna and for the development of a potential innovative vaccine for Shingles," said NgocDiep Le, M.D., Ph.D., Global Chief Medical Officer of Immorna.
  • "If proven successful in clinical studies, JCXH-105 may become a valuable alternative to current standard-of-care to meet the large world-wide medical need for Shingles prevention.
  • In addition, due to the synthetic nature of all JCXH-105 vaccine components, there are no raw material limitations or production bottlenecks."
  • This Phase 1 study is a randomized, double-blinded, multi-center, active-controlled study to assess the safety, immunogenicity, and determine the Recommended Phase 2 Dose (RP2D) for JCXH-105.

VarmX Raises €30 Million Series B2 Financing for IND Approval and Preparations for Pivotal Trial

Retrieved on: 
Thursday, May 25, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Anticoagulant, European Innovation Council, Bleeding, LSP, Destiny of X, BGV, Patient, Risk, Blood, Series, European, LEH, FIH, Thrombosis, EIC, IND, International Society on Thrombosis and Haemostasis, International Society, Safety, Pharmaceutical industry, Birth control

VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces it has successfully raised an additional €30 million in a Series B2 financing round.

Key Points: 
  • VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces it has successfully raised an additional €30 million in a Series B2 financing round.
  • Existing investors EQT Life Sciences (formerly LSP), Inkef, Lundbeckfonden BioCapital, Ysios Capital, BioGeneration Ventures (BGV), InnovationQuarter (IQ) and Libertatis Ergo Holding (LEH) all participated in the Series B2 round.
  • The proceeds from the financing will enable VarmX to obtain investigational new drug (IND) approval for its lead compound VMX-C001 and to complete preparations for the pivotal clinical trial, including large scale manufacturing.
  • VarmX has completed enrollment of VMX-C001’s first-in-human (FIH) study, to demonstrate safety and provide clinical proof of concept of the compound.

InProTher Announces EUR 6M Seed Financing with the Participation of the European Innovation Council Fund to Develop First-In-Class Cancer Immunotherapy

Retrieved on: 
Wednesday, May 24, 2023
Survival rate, Adenoviridae, European Innovation Council, Herv, Cancer, Venture capital financing, Breast, CMO, RNA, Immunotherapy, Doctor of Philosophy, HERV, Manager, EUR, Koala retrovirus, Novartis, MD, Investment, Immune system, Novo Nordisk Foundation, Drug development, FIH, Growth, Merck, BII, EIC, Seed, MPM, SME, Pharmaceutical industry, Management, Security (finance), EU

The financing will enable InProTher to advance its lead drug candidate, IPT001, a first-in-class immunotherapy against solid tumors, into clinical development.

Key Points: 
  • The financing will enable InProTher to advance its lead drug candidate, IPT001, a first-in-class immunotherapy against solid tumors, into clinical development.
  • InProTher has generated robust pre-clinical, proof-of-concept data that demonstrates therapeutic potential for multiple oncology indications including pancreatic, ovarian, breast and prostate cancer.
  • Jordi Naval, Chief Executive Officer of InProTher said: "InProTher is shifting the paradigm in cancer immunotherapy and is at an exciting phase of growth.
  • The Seed round of EUR 6M includes private investors and a convertible loan from EICF.

InProTher Announces EUR 6M Seed Financing with the Participation of the European Innovation Council Fund to Develop First-In-Class Cancer Immunotherapy

Retrieved on: 
Wednesday, May 24, 2023
Survival rate, Adenoviridae, European Innovation Council, Herv, Cancer, Venture capital financing, Breast, CMO, RNA, Immunotherapy, Doctor of Philosophy, HERV, Manager, EUR, Koala retrovirus, Novartis, MD, Investment, Immune system, Novo Nordisk Foundation, Drug development, FIH, Growth, Merck, BII, EIC, Seed, MPM, SME, Pharmaceutical industry, Management, Security (finance), EU

The financing will enable InProTher to advance its lead drug candidate, IPT001, a first-in-class immunotherapy against solid tumors, into clinical development.

Key Points: 
  • The financing will enable InProTher to advance its lead drug candidate, IPT001, a first-in-class immunotherapy against solid tumors, into clinical development.
  • InProTher has generated robust pre-clinical, proof-of-concept data that demonstrates therapeutic potential for multiple oncology indications including pancreatic, ovarian, breast and prostate cancer.
  • Jordi Naval, Chief Executive Officer of InProTher said: "InProTher is shifting the paradigm in cancer immunotherapy and is at an exciting phase of growth.
  • The Seed round of EUR 6M includes private investors and a convertible loan from EICF.